These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33850883)

  • 41. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Efficacy and Potential Application of Neoadjuvant Chemotherapy in Patients with IIIa Stage Non-small Cell Lung Cancer].
    Tang C; Qin S; Wu W; Wu Y; Zhang T
    Zhongguo Fei Ai Za Zhi; 2017 Feb; 20(2):100-106. PubMed ID: 28228221
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC).
    Chiu LC; Lin SM; Lo YL; Kuo SC; Yang CT; Hsu PC
    Vaccines (Basel); 2021 Jun; 9(7):. PubMed ID: 34201650
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant camrelizumab, nab-paclitaxel, and carboplatin in patients with stage IB-IIIA non-small cell lung cancer (NANE-LC): a study protocol of prospective, single-arm, multicenter, phase II study.
    Zhou H; Lin L; Qin T; Ren W; Tan Y; Yang Q; Xu H; Xie X; Chen Y; Liu S; Li X; Li Z; Hu H; Yu Y; Yao H
    J Thorac Dis; 2021 Nov; 13(11):6468-6475. PubMed ID: 34992825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Preliminary Efficacy Evaluation of Neoadjuvant Immunotherapy Combined with 
Chemotherapy in Resectable Non-small Cell Lung Cancer].
    Zhou S; Hao X; Yu D; Liu S; Cao X; Su C; Song X; Xiao N; Li Y; Yang W; Zhao D; Wang J; Liu Z; Xu S
    Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):420-425. PubMed ID: 34024062
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer.
    Qi Y; Gu L; Shen J; Yao Y; Zhao Y; Lu S; Chen Z
    Front Oncol; 2023; 13():1194100. PubMed ID: 37655106
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
    Yao Y; Tang D; Gao W; Zhang H
    Front Surg; 2022; 9():843987. PubMed ID: 35449550
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thoracoscopic radical resection in the treatment of NSCLC patients (stage IIIA) after neoadjuvant chemotherapy.
    Zhao L; Zhang L; Gong F; Xu J
    J BUON; 2021; 26(2):313-319. PubMed ID: 34076974
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
    Harper P
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neoadjuvant targeted therapy versus targeted combined with chemotherapy for resectable EGFR-mutant non-small cell lung cancer: a retrospective controlled real-world study.
    Shao W; Liu Z; Li B; Chen F; Liu J; Li H; Guo H
    Front Oncol; 2024; 14():1349300. PubMed ID: 39081712
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
    Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
    Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postoperative pathological complete response in a patient with PD‑L1‑negative stage IIIB lung squamous cell carcinoma following neoadjuvant tislelizumab treatment combined with chemotherapy: A case report and literature review.
    Cui G; Qu D; Bai Y; Sun X; Li Y; Yang Y
    Oncol Lett; 2023 Sep; 26(3):388. PubMed ID: 37559583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Robotic-assisted thoracic surgery following neoadjuvant chemoimmunotherapy in patients with stage III non-small cell lung cancer: A real-world prospective cohort study.
    Gao Y; Jiang J; Xiao D; Zhou Y; Chen Y; Yang H; Wang L; Zeng J; He B; He R; Li M; Liu Z
    Front Oncol; 2022; 12():969545. PubMed ID: 35992784
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC).
    Wang Q; Qi C; Luo J; Xu N; Xu MT; Qiang Y; Zhang C; Shen Y
    Front Oncol; 2023; 13():1239451. PubMed ID: 38205138
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Hamada A; Soh J; Hata A; Nakamatsu K; Shimokawa M; Yatabe Y; Oizumi H; Tsuboi M; Horinouchi H; Yoshino I; Tanahashi M; Toyooka S; Okada M; Yokomise H; Yamashita M; Nishimura Y; Yamamoto N; Nakagawa K; Mitsudomi T
    Clin Lung Cancer; 2021 Nov; 22(6):596-600. PubMed ID: 34034990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer.
    Tfayli A; Al Assaad M; Fakhri G; Akel R; Atwi H; Ghanem H; El Karak F; Farhat F; Al Rabi K; Sfeir P; Youssef P; Mansour Z; Assi H; Haidar M; Abi Ghanem A; Khalifeh I; Boulos F; Mahfouz R; Youssef B; Zeidan Y; Bejjany R; Khuri F
    Cancer Med; 2020 Nov; 9(22):8406-8411. PubMed ID: 32991781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Perioperative safety and feasibility outcomes of stage IIIA-N2 non-small cell lung cancer following neoadjuvant immunotherapy or neoadjuvant chemotherapy: a retrospective study.
    Huang Z; Wu Z; Qin Y; Zhao Y; Xuan Y; Qiu T; Liu A; Dong Y; Su W; Du W; Yun T; Wang L; Liu D; Sun L; Jiao W
    Ann Transl Med; 2021 Apr; 9(8):685. PubMed ID: 33987383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series.
    Wang Z; Qiang Y; Shen Q; Zhu XX; Song Y
    Front Oncol; 2022; 12():779251. PubMed ID: 35321437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.